Skip to main content
Top
Published in: BMC Psychiatry 1/2007

Open Access 01-12-2007 | Research article

A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients

Authors: Paul Mackin, David R Bishop, Helen MO Watkinson

Published in: BMC Psychiatry | Issue 1/2007

Login to get access

Abstract

Background

Patients with severe mental illness are at increased risk for metabolic and cardiovascular disease. A number of recent guidelines and consensus statements recommend stringent monitoring of metabolic function in individuals receiving antipsychotic drugs.

Methods

We conducted a prospective cohort study of 106 community-treated psychiatric patients from across the diagnostic spectrum from the Northeast of England to investigate changes in metabolic status and monitoring practices for metabolic and cardiovascular disease. We undertook detailed anthropometric and metabolic assessment at baseline and follow-up, and examined clinical notes and hospital laboratory records to ascertain monitoring practices.

Results

A high prevalence of undiagnosed and untreated metabolic disease was present at baseline assessment. Mean follow-up time was 599.3 (SD ± 235.4) days. Body mass index (p < 0.005) and waist circumference (p < 0.05) had significantly increased at follow-up, as had the number of individuals who were either overweight or obese. Fifty-three per cent of individuals had hypertriglyceridemia, and 31% had hypercholesterolemia, but only 7% were receiving lipid-lowering therapy. Monitoring practices were poor. Recording of measures of adiposity occurred in 0% of individuals, and > 50% of subjects had neither blood glucose nor lipids monitored during the follow-up period.

Conclusion

This cohort has a high prevalence of metabolic disease and heightened cardiovascular risk. Despite the publication of a number of recommendations regarding physical health screening in this population, monitoring rates are poor, and physical health worsened during the follow-up period.
Literature
1.
2.
3.
go back to reference Taylor D, Young C, Esop R, Paton C, Walwyn R: Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry. 2004, 185: 152-156. 10.1192/bjp.185.2.152.CrossRefPubMed Taylor D, Young C, Esop R, Paton C, Walwyn R: Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry. 2004, 185: 152-156. 10.1192/bjp.185.2.152.CrossRefPubMed
4.
go back to reference Mackin P, Watkinson HM, Young AH: Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia. 2005, 48 (2): 215-221. 10.1007/s00125-004-1641-y.CrossRefPubMed Mackin P, Watkinson HM, Young AH: Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia. 2005, 48 (2): 215-221. 10.1007/s00125-004-1641-y.CrossRefPubMed
5.
go back to reference Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC: Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care. 2006, 29 (4): 786-791. 10.2337/diacare.29.04.06.dc05-1261.CrossRefPubMed Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC: Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care. 2006, 29 (4): 786-791. 10.2337/diacare.29.04.06.dc05-1261.CrossRefPubMed
6.
go back to reference Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA: Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006 Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA: Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006
7.
go back to reference De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J: Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health. 2006, 2: 14-10.1186/1745-0179-2-14.CrossRef De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J: Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health. 2006, 2: 14-10.1186/1745-0179-2-14.CrossRef
8.
go back to reference Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004, 65 (2): 267-272. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004, 65 (2): 267-272.
9.
go back to reference Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora J, Jones P: Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007 Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora J, Jones P: Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007
10.
go back to reference Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. 2002, National Institute for Clinical Excellence Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. 2002, National Institute for Clinical Excellence
11.
go back to reference Bipolar disorder: The Management of bipolar disorder in adults, children and adolescents, in primary and secondary care. 2006, National Institute for Clinical Excellence Bipolar disorder: The Management of bipolar disorder in adults, children and adolescents, in primary and secondary care. 2006, National Institute for Clinical Excellence
12.
go back to reference Cohn TA, Sernyak MJ: Metabolic monitoring for patients treated with antipsychotic medications. Canadian journal of psychiatry. 2006, 51 (8): 492-501.PubMed Cohn TA, Sernyak MJ: Metabolic monitoring for patients treated with antipsychotic medications. Canadian journal of psychiatry. 2006, 51 (8): 492-501.PubMed
13.
go back to reference Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353 (12): 1209-1223. 10.1056/NEJMoa051688.CrossRefPubMed Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353 (12): 1209-1223. 10.1056/NEJMoa051688.CrossRefPubMed
14.
go back to reference De Hert M, van Eyck D, De Nayer A: Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol. 2006, 21 Suppl 2: S11-5. 10.1097/01.yic.0000201496.23259.85.CrossRefPubMed De Hert M, van Eyck D, De Nayer A: Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol. 2006, 21 Suppl 2: S11-5. 10.1097/01.yic.0000201496.23259.85.CrossRefPubMed
15.
go back to reference Levy JC, Matthews DR, Hermans MP: Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998, 21 (12): 2191-2192. 10.2337/diacare.21.12.2191.CrossRefPubMed Levy JC, Matthews DR, Hermans MP: Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998, 21 (12): 2191-2192. 10.2337/diacare.21.12.2191.CrossRefPubMed
16.
go back to reference Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes. 1979, 28 (12): 1039-1057. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. Diabetes. 1979, 28 (12): 1039-1057.
17.
go back to reference SPSS: SPSS for Windows, version 11. 2001, Chicago, IL , SPSS inc. SPSS: SPSS for Windows, version 11. 2001, Chicago, IL , SPSS inc.
18.
go back to reference Alberti KG, Zimmet P, Shaw J: Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006, 23 (5): 469-480. 10.1111/j.1464-5491.2006.01858.x.CrossRefPubMed Alberti KG, Zimmet P, Shaw J: Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006, 23 (5): 469-480. 10.1111/j.1464-5491.2006.01858.x.CrossRefPubMed
19.
go back to reference Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, Bjorntorp P, Tibblin G: The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes. 1985, 34 (10): 1055-1058. 10.2337/diabetes.34.10.1055.CrossRefPubMed Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, Bjorntorp P, Tibblin G: The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes. 1985, 34 (10): 1055-1058. 10.2337/diabetes.34.10.1055.CrossRefPubMed
20.
go back to reference Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE: Abdominal adiposity and coronary heart disease in women. Jama. 1998, 280 (21): 1843-1848. 10.1001/jama.280.21.1843.CrossRefPubMed Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE: Abdominal adiposity and coronary heart disease in women. Jama. 1998, 280 (21): 1843-1848. 10.1001/jama.280.21.1843.CrossRefPubMed
21.
go back to reference Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000, 177: 212-217. 10.1192/bjp.177.3.212.CrossRefPubMed Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000, 177: 212-217. 10.1192/bjp.177.3.212.CrossRefPubMed
22.
go back to reference Mukherjee S, Schnur DB, Reddy R: Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989, 1 (8636): 495-10.1016/S0140-6736(89)91392-5.CrossRefPubMed Mukherjee S, Schnur DB, Reddy R: Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989, 1 (8636): 495-10.1016/S0140-6736(89)91392-5.CrossRefPubMed
23.
go back to reference Gough SC, O'Donovan M C: Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. J Psychopharmacol. 2005, 19 (6 Suppl): 47-55. 10.1177/0269881105058380.CrossRefPubMed Gough SC, O'Donovan M C: Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. J Psychopharmacol. 2005, 19 (6 Suppl): 47-55. 10.1177/0269881105058380.CrossRefPubMed
Metadata
Title
A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients
Authors
Paul Mackin
David R Bishop
Helen MO Watkinson
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2007
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-7-28

Other articles of this Issue 1/2007

BMC Psychiatry 1/2007 Go to the issue